ESR1 and breast cancer: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) trial compared neoadjuvant tamoxifen, anastrozole or both for 3 months, in 330 women with ER+ invasive, non-metastatic operable, or locally advanced but potentially operable breast cancer.